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ABSTRACT 
A purpose of chemical health risk assessment is to characterize the nature and size of the 
health risk associated with exposure to chemicals, including identification of a dose below 
which toxic effects are not expected or negligible. This is usually based on analysis of dose-
response data from toxicity studies on animals. Traditionally the dose-response in animals has 
been analyzed employing the No-Observed-Adverse-Effect-Level (NOAEL) approach, but 
because of the several flaws of this approach it is to a greater and greater extent being 
replaced by the so called Benchmark Dose (BMD) approach.  
Previous evaluations of how to design studies in order to obtain as much information as 
possible from a limited number of experimental animals have revealed the importance of 
including high doses. However, these studies have not taken the distress of the laboratory 
animals, which is likely to be higher at high doses, into account.  
The overall aim of the present thesis was to examine how study designs, especially with dose 
groups of unequal size, affect the quality of BMD estimates and level of animal distress.  
In Paper I our computer simulations concerning the appropriateness of using nested models 
in BMD modelling of continuous endpoints indicate that it is problematic to calculate BMD 
on the basis of simpler models and that they should be used with caution in connection with 
risk assessment as they may result in underestimations of the true BMD.  
In Paper II-III our computer simulations of toxicity testing with unequal group sizes showed 
that better information about dose-response can be obtained with designs that also reduce the 
level of animal distress. 
In Paper IV we interviewed members of the Swedish Animal Ethics Committees concerning 
how the number of animals used in toxicity tests might be weight against the distress of the 
individual animal. Their opinions concerning whether it is preferable to use fewer animals 
that suffer more rather than a large number of animals that suffer a little, differed 
considerably between individuals. However, there were no statistically significant differences 
in relation to the fact that respondent were either researchers, political representatives or 
representatives of animal welfare organizations. 
In Paper V the results from Paper IV and the simulation techniques in Paper II were 
combined to evaluate how toxicity tests could be designed to obtain as much information as 
possible at a limited ethical cost, with respect to both the number of animals used and their 
individual distress. The most ethically efficient design depended on what constituted the 
ethical cost and how large that ethical cost was.  
In conclusion, this thesis describes the potential to use BMD-aligned study design as a mean 
for refinement of animal toxicity testing. In addition, new strategies for model selection and 
quantitative measures of ethical weights are presented.  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Vi utsätts ständigt i olika grad för kemikalier som potentiellt kan vara skadliga för oss. 
Hälsoriskbedömningar av dessa kemikalier görs för att avgöra när åtgärder behöver sättas in 
för att begränsa vår exponering. Riskbedömningarna mynnar ofta ut i sättandet av riktvärden, 
såsom acceptabla dagliga intag. Riktvärdena baseras ofta på djurförsök där man identifierar 
NOAEL-värden, dvs. den högsta dos som inte ger en statistiskt säkerställd effekt. NOAEL 
metodiken har dock brister och därför använder allt fler Benchmark Dos (BMD) metoden. En 
fördel med BMD-metoden är att den tar hänsyn till osäkerheter i data på ett bättre sätt.  
Flera tidigare undersökningar har studerat hur man designar ett toxikologiskt försök för att få 
ut så mycket information som möjligt. Dessa studier har utgått ifrån ett bestämt totalt antal 
försöksdjur och bland annat visat att det är viktigt att det förekommer höga doser i försöken. 
Dock har inga tagit hänsyn till de etiska aspekterna av försöket. I samband med toxikologiska 
tester är det till exempel rimligt att tänka sig att djur som utsätts för en hög dos lider mer än 
djur som får en lägre dos. 
Det övergripande målet var därför att studera hur designen av toxikologiska försök kan 
förbättras så att likvärdig, eller bättre, information kan tas fram med lika mycket eller mindre 
lidande hos försöksdjuren. 
Under arbetet med våra datasimuleringar observerade vi att den vedertagna BMD-metodiken 
i vissa fall kan leda till värden som underskattar risken. I studie I undersökte vi varför, hur 
ofta och när detta inträffar. Vi visade att fenomenet uppkommer när alltför enkla matematiska 
modeller väljs för att beskriva sambandet mellan dos och effekt.  
I studie II-III har vi med datorsimuleringar undersökt förhållandet mellan kvalitén på den 
information man får från ett toxikologiskt och hur försöket läggs upp. Vi visade att i flera fall 
kan kvaliteten på denna information förbättras samtidigt som djurlidandet minskas. 
I studie IV intervjuade vi ledamöterna i de svenska djurförsöksetiska nämnderna om hur 
tecken på djurs lidande bör värderas etiskt. Vilket är det minst dåliga alternativet; att ha ett 
fåtal djur som utsätts för ett större lidande eller att använda fler djur som lider mindre? 
Individuella ledamöter resonerade väldigt olika kring dessa frågor. Vi såg dock inga säkra 
skillnader mellan forskare, politiker eller representanter från djurskyddsorganisationer. 
I studie V kombinerade vi resultaten från studie IV med datorsimuleringarna från studie II 
för att undersöka hur ett toxikologiskt försök skulle kunna läggas upp för att få ut mest 
information givet en fast etisk kostnad för försöket, där den etiska kostnaden var beroende 
både av antalet djur i försöket och av djurens lidande. Det visade sig att det finns potentiella 
etiska vinster i förändrad studiedesign, beroende på hur den etiska kostnaden definieras. 
Sammantaget visar avhandlingen att det finns en potential att minska djurs lidande utan att 
förlora vetenskaplig information genom att använda moderna metoder för dos-responsanalys 
samt att djurförsök kan värderas både utifrån antalet djur och utifrån deras lidande.  
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1 INTRODUCTION 
Current toxicity testing involves use of many non-human animals (hereafter simply referred 
to as just “animals”), which has been criticized on both ethical (Regan, 1983; Singer, 2009) 
and scientific grounds (see Knight, 2013 for a review). This thesis does not resolve such 
controversies, but focuses on how to use animals as efficiently as possible, from a 
mathematical and statistical perspective. In addition, the ethical aspects of animal 
experiments are introduced as a limiting factor in optimization of experimental design. Many 
of the conclusions in Papers I-III are also relevant for in vitro toxicity testing. 
1.1 RISK ASSESSMENT 
An aim of quantitative chemical risk assessment is to assess the risk associated with the 
chemical exposure in a target population such as workers or the general public. The risk 
assessment process consists of 4 different steps (Figure 1) (NRC, 1983; WHO/IPCS, 2004): 
 
Figure 1. The four parts of chemical risk assessment. 
 
During the exposure characterization, the exposure to chemical through various sources is 
estimated. Chemicals can be taken up via the gastrointestinal tract, via inhalation or through 
the skin and the sources of exposure varies between different chemicals and human 
populations. This includes exposures via food, drinks, exposures in the workplace or as 
exposures as results of accidents etc. Finally, at the risk characterization stage all evidence 
from the previous steps is weight together to determine the human risk associated with the 
exposure.  
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The RfDs being determined in the dose-response assessment is derived from so called Points-
of-Departure (PoDs), i.e doses that exert no or acceptably low adverse effect in the study of 
interest. To obtain the RfD, the PoD is divided by a number of different Assessment Factors 
(AF) that take into account the uncertainties resulting from extrapolation of animal data to 
humans, as well as other uncertainties:  
RfD =
𝑃𝑜𝐷
𝐴𝐹
   (US EPA, 2002) 
The traditional AF of 100 consists of two parts, a factor of 10 designed to take into account 
the toxicokinetic and toxicodynamic differences between the species tested and humans, 
along with a factor 10 that reflects differences in sensitivity between different human 
individual (ECHA, 2012). Additional assessment factors may also be applied when 
extrapolating from short- to a long-term exposure and/or when utilizing incomplete 
databases. When quantitative information concerning the difference in sensitivity between 
animals and humans or between different individuals are available, chemical specific 
assessment factors should be used instead of the standard assessment factors (Meek et al., 
2002; US EPA, 2002). 
For most chemicals, it is assumed that there is a threshold level of exposure below which 
there is no risk of adverse effects (Dybing et al., 2002; Edler et al., 2002), but it is extremely 
difficult or even impossible to determine the existence of such a threshold based on 
experimental data (Slob, 1999; Slob, 2007). For genotoxic carcinogens it is however 
generally assumed that there is no threshold for the risk because a single genotoxic molecule 
could interfere with DNA leading to a mutation and cancer (US. EPA, 2005). This difference 
in the risk assessment of genotoxic carcinogens and other toxicants has its origins in the late 
1970´s, when similarities between the effects of genotoxic carcinogens and radiation were 
realized (Bogdanffy et al., 2001). 
1.1.1 No-Observed-Adverse-Effect-Level  
Traditionally, the so-called No-Observed-Adverse-Effect-Level (NOAEL) has been used as 
the PoD. The NOAEL is the highest dose in a study that does not give rise to an adverse 
effect that is statistically significantly different from the effect in the control group (WHO, 
1999). Since it is occasionally very difficult to determine whether an effect is actually adverse 
and relevant to humans the term No-Observed-Effect-Level (NOEL) is sometimes preferred  
(Berry, 1988). The term NOAEL will however be used throughout this thesis.  In studies 
where there is no NOAEL as the effect in all dose groups differs from the control, the RfD 
can be calculated from the Lowest Adverse Effect-Level (LOAEL) instead of the NOAEL, 
usually with application of an additional assessment factor of 3-10 (ECHA, 2012) .  
1.1.2 Benchmark Dose  
The Benchmark dose (BMD) approach (Figure 2) was introduced by Crump to circumvent 
some of the disadvantages connected with the use of the NOAELs to set RfDs (Crump, 
1984). BMD was originally mostly used with quantal data from developmental studies (Allen 
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et al., 1994a; Allen et al., 1994b), but is now used for both other types of experimental data 
and epidemiological data  (Budtz-Jorgensen et al., 2001; Sand et al., 2008).   
Determination of a BMD involves first fitting a dose-response model to the data and then 
interpolating to find which dose that causes a predefined response. That dose is defined as the 
BMD. To account for uncertainty and provide a margin of safety, a two-sided 90% 
confidence interval for the BMD is calculated and the lower limit of that interval, the BMDL, 
is employed instead of the NOAEL to calculate RfDs. The upper limit of this confidence 
interval, the BMDU, is sometimes used to calculate the BMDU/BMDL ratio which provides 
an estimate of the uncertainty in the BMD value. The BMD/BMDL ratio can also be used for 
this purpose but is less good as it is does not take the full uncertainty in the BMD estimation 
into account (Slob, 2014a). The profile likelihood procedure (Venzon and Moolgavkar, 
1988), which is relatively rapid,  is commonly used to calculate the BMDL and BMDU, but 
other approaches have been discussed and used as well, such as the bootstrap and the delta 
methods (Moerbeek et al., 2004).  
The BMD approach has numerous advantages over the usage of the NOAEL (Crump, 1984; 
Davis et al., 2011). The most important, of which is that BMD takes uncertainty into account 
in a proper manner. In a test with smaller dose groups, the NOAEL tends to be higher, giving 
rise to higher RfDs when there is not much data available. This is not reasonable from a 
precautionary perspective. With BMD on the other hand, the use of small groups usually 
results in lower, more precautionary, RfDs.   
 
 
Figure 2. The BMD procedure. After fitting a mathematical model to the dose-response data the BMD is the dose that 
causes a predefined response. The BMDL and BMDU values are the lower and upper limits of the 90% confidence 
interval for the BMD.  
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Another advantage of BMD modeling is that it well suited to handle covariates, such as sex 
(Edler, 2014). Data from females and males can be used simultaneously in the curve fitting 
and the parameters of interest will only be covariate dependent if there is a difference 
between the sexes for those parameters. For the parameters where there is no difference, the 
different groups will share the same parameter, thereby extracting more information. 
Additional differences between the BMD approach and the NOAEL approach are listed in 
Table 1. Despite some reluctance to use the BMD approach (Travis et al., 2005), this method 
has now been implemented as an alternative or preferred approach by many regulatory 
agencies (Brandon et al., 2013; ECHA, 2012; NAC/AEGL, 2001; Solecki et al., 2005; 
USEPA, 1995; WHO, 2009). 
 
Table 1. Comparisons of the BMD and NOAEL approaches (Öberg, 2010; Slob, 2014a; Travis et al., 2005) 
Advantages of the BMD Disadvantages of the BMD 
Takes uncertainty into account in a 
proper manner. 
More difficult to perform. 
More suitable for simultaneous 
analysis and pooling of datasets. 
Less intuitive. 
Promotes good quality experiments. Less well known. 
Takes the shape of the dose-effect 
curve into account. 
Requires greater harmonization and consensus 
regarding the choice of models, benchmark responses 
etc. 
The choice of critical effect size can 
reflect the severity of the effect. 
 
Less dependent on study design.  
Partially solves the “LOAEL only” 
problem. 
 
Set on a continuous scale.  
BMD ratios are more informative 
than NOAEL ratios. 
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1.1.2.1 Quantal data  
With quantal data, also referred to as dichotomous or dose-response data, the outcomes are 
incidences, e.g. number of animals with tumors. Since each animal/human/cell either 
responds or not, quantal data lie between 0% and 100%. With such data the BMD is defined 
as the dose that gives rise to a Benchmark Response (BMR), most often defined as either an 
increased additional risk or extra risk:  
𝐴𝑑𝑑𝑖𝑡𝑖𝑜𝑛𝑎𝑙 𝑅𝑖𝑠𝑘 = 𝑃(𝑥) − 𝑃(0) 
𝐸𝑥𝑡𝑟𝑎 𝑅𝑖𝑠𝑘 =
𝑃(𝑥) − 𝑃(0)
1 − 𝑃(0)
 
An extra risk of 10% is recommended as default for the BMR by both EFSA (EFSA, 2009) 
and US EPA (US EPA, 2012). One advantage of using extra rather than additional risk is that 
a BMD based on extra risk and calculated with a multivariate method, will always be lower 
than the corresponding value calculated from each endpoint separately (Gaylor et al., 1998). 
It has also been suggested that the BMR could be defined as the effect at the Signal-to-Noise-
Cross-over-Dose, i.e. a dose where the extra risk is equal to the background noise (Sand et al., 
2011). 
A multitude of dose-response models have been used for quantal data (Sand et al., 2008).  
Since the results of developmental toxicity studies are a special kind of quantal data the pups 
from the same litter are correlated. BMD modeling of developmental toxicity data therefore 
uses special types of models to take intra-literal effects into account (Kodell et al., 1991; Rai 
and Vanryzin, 1985). 
1.1.2.2  Continuous data 
Body weight, organ weights and enzyme levels are typical continuous data, also referred to as 
dose-effect data. For such data each animal has its own magnitude of effect and the arithmetic 
or geometric means of the different dose groups are usually compared. One important 
difference between quantal and continuous data is the inherent presence of an upper limit of 
100% in the case of the former. Although most continuous effects have a lower and upper 
limit, the value of it is not known beforehand.  
Originally continuous data were often modelled using linear models, power models or 
polynomials (Allen et al., 1994a; Allen et al., 1996; Crump, 1984; Kavlock et al., 1995). 
However, such models do not level off at higher doses and are thereby clearly not suitable for 
some datasets. As a consequence, there has been a stronger focus on models that do have the 
ability to level off at higher doses (US EPA, 2012),  such as the Hill model (Barton et al., 
1998; Murrell et al., 1998) and exponential model (Slob, 2002). Both the Hill model and the 
exponential model can be parametrized as families of nested models, i.e. the simpler models 
within a family can be derived from the more complex ones by fixing parameters in the latter 
(Figure 3).   
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Figure 3. The nested set of exponential models (Slob, 2002).  Model 1 is obtained from model 2 by setting b = 0 and 
model 2 from model 3, 4 or 5 by setting c = 0 and/or d = 1. A more complicated model is selected if the fit is 
significantly better according to a likelihood ratio test. This image is taken from Ringblom et al (2014) 
 
When Slob and Setzer (2014) analyzed a large set of historical data sets including both in 
vivo and in vitro endpoints, they found that both the 4-parameter exponential and Hill models 
fitted the data adequately. Fitting the data simultaneously for the same endpoint, but different 
chemicals, gave curves of the same shape for the in vitro endpoints, as well as dose-effect 
curves of similar shape for the in vivo endpoints.  
The different approaches to choosing a BMR for continuous data can be categorized into two 
categories, nonprobabilistic and probabilistic. The original definition was a nonprobabilistic 
definition with the BMR, or cBMR, defined as a percentage change in the mean effect 
compared to the mean background effect: 
𝑐𝐵𝑀𝑅 =
𝑚(𝑥) − 𝑚(0)
𝑚(0)
 
 
The cBMR was later renamed Critical Effect Size (CES) and discussed further by Slob and 
Pieters (Slob and Pieters, 1998). It is has been recommended that the CES should be a low 
but still measurable effect. Having a CES that is too low will lead to extrapolations and heavy 
dependence of the BMD on the model employed (Edler, 2014). Different endpoints therefore 
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requires different CES values (Dekkers et al., 2001). EFSA has proposed a preferred default 
5% as a CES, with modifications if required by toxicological or statistical considerations 
(EFSA, 2009). It has also been suggested that CES values can be set by observing the intra-
animal variation in historical data (Dekkers et al., 2006). 
Other definitions of the BMR for continuous data have been proposed, e.g. as the effect 
corresponding to a percentage of the entire dose-effect span, so that a BMD10 would be 
equivalent to a ED10  (Murrell et al., 1998) or as the dose at that corresponds to where the 
slope of the dose-effect curve changes most rapidly (Sand et al., 2006).  
The simplest probabilistic approach to define a BMR for continuous data is to transform the 
continuous data into quantal data, e.g. by defining a cutoff point such as weight loss of 5% or 
10% as adverse. Any animal with a larger weight loss will be considered a responder and 
animals with less weight loss will be considered a non-responder. This procedure has 
however been criticized since information is lost when the data are quantalized (Crump, 
1995; West and Kodell, 1999).   
The probabilistic hybrid approach proposed by Gaylor and Slikker (1990)  is more advanced. 
Here, the distribution of the effect at each dose level is estimated and the BMD defined as the 
dose that causes a predefined fraction of the animals to exhibit effects greater than a certain 
cut-off level. The U.S EPA supports the use of this procedure as the default approach to 
selecting a BMR, but only if there is no specific change in endpoint that can be considered 
adverse (US EPA, 2012).   
Another important difference between quantal and continuous data is that for continuous data 
is that the latter requires assumptions concerning the distribution of the data (normally 
distributed, lognormally distributed or some other form of distribution).  Shao and Small 
(2013) concluded that incorrect assumptions regarding normality or lognormality exert only 
minor impact on the BMD estimate when the variation is small. The variance of continuous 
data may also be assumed to be consistent at all doses or to change with the effect size. None 
of these assumptions are necessary with quantal data.  
1.1.3 Choice of models and model-averaging techniques.  
Application of different models to the same data will yield different values for the BMD and 
BMDL. As a consequence, there are different methods that guide the choice of which BMD 
and BMDL to use. The different methods rely on the goodness of fit of the model, often 
assessed as the loglikelihood of the fit. An acceptable fit can be examined by comparisons to 
the fit of the full saturated model and/or the fit of the reduced straight line model (Edler, 
2014). While larger and more complex models usually provide better fits they may still be 
less preferable than simpler based on the principle of parsimony.  
In the case of two nested models, statistical theory states that the difference in loglikelihood 
follows a chi-square distribution. This means that in a nested set of models, as with the family 
of exponential models or Hill models, the choice of model can be based on a series of 
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likelihood ratio tests (Figure 3). If addition of a parameter to a simple model does not 
significantly improve the fit the simpler model is retained. Following this procedure for all 
model comparisons in a nested set, a single model can be selected.  
Current EFSA guidelines suggest that the lowest BMDL among the models that pass a 
goodness-of-fit test should be used as the PoD (EFSA, 2009). EPA´s guidelines are less 
conservative, suggesting that the model with the lowest AIC (Akaike Information Criterion) 
should be used as the PoD, unless there is a large difference between the BMDL values 
obtained with the different models (US EPA, 2012).  The AIC takes the likelihood (L) of the 
model fit into account, but penalizes models with many parameters (k): 
𝐴𝐼𝐶 = 2𝑘 − 2𝑙𝑛(𝐿) 
Accordingly, the EPA guidelines result in less conservative estimates of BMDLs than do the 
EFSA guidelines, which on the other hand can be seen as overly conservative.  
Model averaging is a more advanced alternative which takes model uncertainty into 
consideration by weighting the contribution of various models together. The information 
from all of the models rather than only the most conservative or the one with the best fit is 
used to determine the PoD. Bayesian Model Averaging (BMA) has been used in to calculate 
BMDs in several BMD investigations (Dankovic et al., 2007; Morales et al., 2006; Shao and 
Gift, 2014; Simmons et al., 2015). Full scale BMA is both complicated and time-consuming 
which led Buckland and colleagues (1997) to propose simpler model averaging methods that 
also have been used within the BMD field (Faes et al., 2007; Moon et al., 2005; Piegorsch et 
al., 2013; Wheeler and Bailer, 2007; Wheeler and Bailer, 2009b). These frequentist 
procedures commonly relies on estimating model weights based on measures of the model fit 
such as the AIC, the corrected AIC (AICn), Bayesian Information Criterion (BIC) or the 
Kullback Information Criterion (KIC).   
Various non-parametric and semi-parametric procedures for calculating the BMD has been 
suggested (Bhattacharya and Lin, 2010; Guha et al., 2013; Piegorsch et al., 2012; Wheeler 
and Bailer, 2012), but these have so far been used only rarely and not yet incorporated in 
regulatory guidelines.  
The extent to which a model selection or model averaging procedure is conservative or anti-
conservative can be estimated by calculating the coverage rate for the BMDL, i.e. how often 
the BMDL is lower than the true BMD, by using Monte Carlo simulations. Theoretically, the 
coverage rates should be 95%, but it can be substantially different if the model selected is 
different from the “true” model. West and colleagues (2012) have shown that relying solely 
on the AIC for modeling quantal data can lead to substantial undercoverage. Below expected 
coverage rates have also been noted in passing in a study on continuous data (Slob et al., 
2005). 
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1.1.4 Experimental designs 
The efficiency of the design of a toxicological experiment can be evaluated either by Monte 
Carlo simulations (Kavlock et al., 1996; Shao and Small, 2012; Slob, 2014b; Slob et al., 
2005; Weller et al., 1995) or by evaluating or minimizing a design criterion such as the 
expected variance of the parameters (Dette et al., 2009; Holland-Letz and Kopp-Schneider, 
2015; Krewski et al., 2002; Kuljus et al., 2006; Weller et al., 1995). Published reports 
involving any of these approaches are summarized Table 3 in the Results section. Öberg 
(2010) suggested that animal distress could be taken into account when investigating study 
designs, this has not yet been done. 
1.2 ANIMAL EXPERIMENTS 
Animal based research, carried out since the time of ancient Greece (Hajar, 2011), has been 
criticized, not least by the anti-vivisectionist movement that started in Britain during the 
nineteenth century (Rollin, 2006) and off-shoot organizations.  
Today, animals are widely used in medical research and safety testing of chemical. It has 
been estimated that more than 100 million experimental animals according to the EEC 
definition (EEC, 1986) of animals and experiments, were used worldwide during 2005 
(Taylor et al., 2008). While some animals experience little or no distress and/or pain in this 
context, others are subjected to significant discomfort. During 2013 in Canada 38.2% of the 
laboratory animals used were reported to be subjected to procedures that could potentially 
cause moderate-to-severe distress or discomfort, such as major surgical procedures under 
general anesthesia with subsequent recovery or exposure to drugs and chemicals at levels that 
impair physiological systems. 2.5% were reported to be subjected to procedures that could 
potentially cause severe pain near, at, or above the pain tolerance threshold for conscious 
animals, such as  exposure to drugs or chemicals at levels that (may) markedly impair 
physiological systems and which cause death, severe pain, or extreme distress (Canadian 
Council on Animal Care, 1991; Canadian Council on Animal Care, 2015). Although this 
categorization is based on a precautionary approach and the percentages are therefore likely 
to be overestimations, they are nonetheless disturbing.  
1.2.1 Legislation concerning animal experiments 
The laws regulating usage of animals in research are mostly regulated with a utilitarian 
perspective where the chance of positive outcome is weighted against the risk of harm (Vieira 
de Castro and Olsson, 2015). In the USA researchers must adhere to the United States 
Animal Welfare Act (USAWA) (US Department of Agriculture, 2013), which does not 
however, cover rats or mice bred for research purposes, that constitute the lion’s share of all 
animals used in research. Within the EU, researchers must follow the Directive on Animals 
used for scientific purposes (EU, 2010) and all animal experiments must be impartially pre-
evaluated to ensure that the benefits of the experiments outweigh the harm to the animals. In 
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Sweden this evaluation is performed by one of the six regional Animal Ethics Committees 
(AECs), consisting of both researchers and laypersons including representatives for animal 
welfare organizations.  
Other legislation influences the utilization of experimental animals. The EU’s regulation of 
chemicals, REACH, demands the identification and management of the risks linked to all 
chemicals imported into, or produced in the EU in an annual quantity larger than one ton (EC, 
2006a) and Rovida and Hartung (2009) have estimated that fulfilling these demands could 
potentially require the use of 54 million animals before 2018. The REACH legislation do 
however encourage the use of animal free methods (EC, 2006b) and animal-free risk 
assessment, such as read-across, are being utilized to a greater extent (ECHA, 2014; 
Spielmann et al., 2011) 
1.2.2 3R 
The principle of the 3Rs (replacement, reduction and refinement) for animal experiments was 
launched in 1959 (Russell and Burch, 1959) and has now been incorporated in governmental 
legislation in the EU (EU, 2010).  The definition of the 3Rs has changed since the original 
definitions by Russel and Burch. The 3R Declaration of Bologna, defined: 
 “Reduction alternatives are methods for obtaining comparable levels of information from the 
use of fewer animals in scientific procedures, or for obtaining more information from the 
same number of animals. 
Refinement alternatives as methods which alleviate or minimize potential pain, suffering and 
distress, and which enhance animal well-being. 
Replacement alternatives as methods which permit a given purpose to be achieved without 
conducting experiments or other scientific procedures on animals.” (Executive Committee of 
the Congress, 2000) 
In many cases the 3Rs are positively correlated. For instance, refinement methods leading to 
less animal distress often also result in less variable data so that fewer animals are required to 
achieve acceptable scientific power (reduction). However, sometimes the 3Rs can correlate 
negatively, e.g. surgical implantation of telemetry devices for continuous monitoring, which 
may cause distress, can produce better data and consequently reduce the need for animals. 
The conflict between refinement and reduction is also evident in connection with toxicity 
testing. Lowering doses represents a refinement, but then the statistical power of the test will 
also be lowered so that more animals are required. In such situations, there is a lack of 
guidance concerning which R to prioritize (de Boo et al., 2005). 
For an example, the EU directive on the protection of animals used for scientific purposes 
states that the benefits expected must outweigh the ethical cost i.e. a cost-benefit analysis 
must be performed for each individual animal (EU, 2010). However, this directive provides 
no general guidance concerning the relative priorities that should be assigned to reduction and 
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refinement. Consider a hypothetical example: A planned experiment that could be quite 
distressful involves two individual rats named Sprague and Dawley, among others. In 
experimental setup 1 both would be among the animals used and the expected benefit is 
considered to be larger than the ethical cost. If either Sprague or Dawley were removed, 
scientific power would be lost and no conclusion could then be drawn from the experiment. 
Therefore, if the cost-benefit analysis for the entire experiment is acceptable, it must include 
both Sprague and Dawley and their use is thus also acceptable on the basis of individual cost-
benefit analysis. 
The alternative experimental setup 2, offers the same potential benefits as setup 1, but 
Dawley no longer needs to be used. However an additional blood sample has to be taken 
from Sprague, thereby increasing his distress slightly. This experiment would still be 
considered ethically acceptable if the overall stress experienced by Sprague is outweighed by 
the benefits, but which setup should be chosen? The EU directive states that the individual 
animal must be considered, but Sprague suffers more in setup 2 whereas Dawley suffers more 
in setup 1. Such a decision must be based on ethical, not legal considerations. 
1.2.3 Ethical considerations regarding reduction versus refinement 
The choice between reduction and refinement is not entirely straightforward, especially since 
experimental animals are usually killed at the end of the experiment. Moreover, these animals 
are bred for this specific purpose and in the long run a reduction in the usage of animals will 
lead to fewer animals being born. It therefore becomes a conflict between quantity and 
quality of life, as discussed further by Sandøe and Christiansen (2007) . 
Some argument support prioritization of refinement over reduction under all circumstances. 
For instance, animal rights philosopher Tom Regan advocates the worse-off principle in 
general whenever there is a conflict between rights. This principle states that if we must 
choose between overriding the rights of many or a few, it is better to override the rights of 
many, if harming the few will leave them worse off than the any of the many would be if the 
other option was chosen (Regan, 1983).  
In many instances a hedonistic utilitarian, who are interested in the maximizing the amount of 
pleasure or wellbeing, have good reasons to prioritize refinement over reduction. If the 
experimental animals have a life generally worth living, reduction is even ethically 
questionable since it will lead to fewer animals being born and therefore less total wellbeing, 
a conclusion that most people probably find counterintuitive. Furthermore, it is not clear 
whether it is generally preferable to have more individuals, even if each has a positive 
wellbeing.  One problem with maximizing total happiness in this manner is that it easily leads 
to the so-called Repugnant Conclusion (RC) as follows:  
In Figure 4, the heights of the bars represent the positive wellbeing of a group of individuals, 
and the width represents the number of individuals in each group. In Scenario A only 
contains individuals with a high wellbeing. Scenario A+ is similar to scenario A, but with the 
addition of more individuals with less, although still positive wellbeing, so in scenario A+ the 
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total wellbeing is greater.  Scenario B contains the same number of individuals as A+ each 
with the same wellbeing which is slightly higher than the average in A+, it is then reasonable 
to consider B preferable to A+.  If B is better than A+ and A+ is better than A, then B should 
be better than A.    
If this process is repeated almost indefinitely, scenario Z in which an enormous number of 
individuals have a wellbeing that is barely high enough to be better than not living, will be 
reached. Z, which involves the most wellbeing, should be the best scenario of them all.  This 
conclusion, that a world in which everyone has a life barely worth living, is better than a one 
which smaller number of individuals have a wonderful life is referred to as the Repugnant 
Conclusion (Figure 4).  
Those who defend utilitarian welfare aggregation have dealt with this conclusion either by 
arguing that there is something wrong in the arguments involved (Blackorby et al., 1997; Ng, 
1989) or that it is not actually repugnant (Ng, 1989; Tännsjö, 2002). Carlson (1998) has 
discussed a similar situation in which all cases (A-Z) include negative wellbeing with lives 
worth avoiding and concluded that those who are worse off should reasonably be given 
higher weight when aggregating the wellbeing. In an animal experiment this would mean that 
refinement should generally be given higher priority than reduction, although not in all cases. 
There will be situations where it is better for fewer animals to experience more negative 
wellbeing than for more animals to experience less negative wellbeing. 
 
Figure 4. The Repugnant Conclusion.  See text for explanation. 
  13 
If killing animals always should be avoided it can be considered that reduction always should 
have precedence over refinement. This “badness-of-killing argument” has however been 
critized as it is not in line with how animal ethics are handled in other parts of society, such as 
concerning production of meat (Hansen et al., 1999; Olsson et al., 2012). 
In the absence of normative prioritizations concerning reduction and refinement, ethical 
decisions are made on case by case basis, which implicitly or explicitly requires a measure of 
ethical cost, preferably on a cardinal scale where the ethical cost of using an animal is 
proportional to the ethical severity of that use. This scale must also be additive so that the 
ethical cost of using a number of animals is equal to the sum of the ethical cost for each 
individual animal.  
There are few point and score systems for the quantitative ethical evaluation of animal 
experiments described to date (Porter, 1992; Stafleu et al., 1999) but their cardinality is 
questionable at best (Table 2).  Moreover, their primary aim was to guide harm-benefit 
analysis rather than specific choices between reduction and refinement. 
Table 2. Ethical cost points concerning the number of animals in the scoring system developed by Porter (Porter, 
1992).  This scoring is not cardinal since the cost is not proportional to the number of animals.  
Animals used Cost points 
1-5 1 
6-10 2 
11-20 3 
21-100 4 
>101 5 
 
 
Other, more detailed scoring sheets for clinical signs of pain, distress and suffering have been 
developed for use with laboratory animals (Morton and Griffiths, 1985; Scharmann, 1999). 
These are often semi-quantitative and employed to determine when the animals should be 
given analgesia or euthanized because their suffering exceeds what is deemed acceptable. 
Accordingly, these scoring schemes involve the assessment of individual animals during the 
course of an experiment and they cannot in their present form be used directly to decide 
between reduction and refinement in connection with experimental design.  
A set of cardinal weights for animal experiments could be developed using an approach 
similar to the Person Trade-Off (PTO) technique, originally known as the equivalence 
technique, that has been used to derive Quality Adjusted Life Years (Murray and Lopez, 
1996). With the PTO interviewees are asked questions such as: “If there are x people in 
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adverse health situation A and y people in adverse health state B and if you can only help 
(cure) one group (for example due to limited time or limited resources) which one would you 
choose to help?”(Torrance, 1986). 
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2 AIMS 
The general objective of this thesis was to improve BMD modeling in relationship to the use 
of experimental animals in toxicological experiments. The specific objectives were as 
follows: 
 
Paper I 
To investigate under what circumstances and how frequently BMDL coverage with 
continuous data are below the nominal level. A secondary aim was to investigate the 
coverage of the NOAEL in relation to the true BMD. 
 
Paper II  
To investigate whether and under what circumstances experimental designs involving dose 
groups of unequal size can both result in less animal distress and provide more reliable 
estimates of the BMD for quantal data.  
 
Paper III 
To investigate whether and under what circumstances experimental designs involving dose 
groups of unequal size can both result in less animal distress and provide more reliable 
estimates of the BMD for continuous data.  
 
Paper IV 
To determine cardinal ethical weights for toxicity testing, as well as investigate how these 
differ between different categories of responders.  
 
Paper V 
To investigate the impact of taking ethical cost into consideration in connection with 
optimization of dose-response studies.  
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3 METHODS 
In Paper I the BMDL coverage rates were investigated by simulating continuous data from a 
sigmoidal exponential curve and then calculating the BMDL values with a standard nested set 
of exponential models (Figure 3). One of these models was selected on the basis of likelihood-
ratio tests as described by Slob (2002). Utilizing a model from earlier simulations studies as the 
true underlying model,  Monte Carlo simulations were performed to investigate how often the 
BMDL and the NOAEL was higher than the true BMD, and how much higher they were  
In Paper II the effects of using unequal numbers of animals in the different dose groups for 
toxicological studies, with in total 200 animals, on the quality of BMD estimates were 
investigated using Monte Carlo simulations on quantal data. Six different dose-response models 
commonly used in BMD calculations for quantal data were used in the simulations and in the 
re-estimations. All six were used as true models, by fitting them to two different datasets from 
an NTP (National Toxicology Program) cancer study on furan (NTP, 1993); one on the 
incidence of hepatocellular carcinoma, without background incidence, and one on the incidence 
of mononuclear cell leukemia, where there was a background incidence of 16%. Thus, 12 (2×6) 
different “true” curves were used in the simulation. Nine different dose placements were 
evaluated, ranging from very low doses to very high doses, each with 85 different distributions 
of animals between four dose groups. An AIC-based model averaging approach was used and 
the performance of a specific design evaluated using the root mean squared error (RMSE) of the 
AIC-averaged BMD estimates and by calculating the ratio between AIC-averaged BMDU and 
the AIC-averaged BMDL. The animal distress was assumed to be proportional to dose. 
In Paper III the effects of using unequal numbers of animals in the different dose groups for 
toxicological studies on the quality of BMD estimates were investigated using Monte Carlo 
simulations on continuous data. The simulation step was based on four different hypothetical 
“true” curves. The curves included two sigmoidal curves, one that either clearly levelled off 
within the covered dose-effect span and one that barely leveled off within the dose-effect span 
as well as two models that did not level off. Designs with either 40, 80 or 200 animals in total 
were evaluated as these are common study sizes in OECD guidelines (OECD, 2012). Nine 
different dose placements were evaluated, ranging from very low doses to very high doses, each 
with 85 different distributions of animals between four dose groups. An AIC-based model 
averaging approach was used and the performance of a specific design evaluated using the root 
mean squared error (RMSE) of the AIC-averaged BMD estimates. The animal distress was 
assumed to be proportional to dose. 
In Paper IV members of the Swedish Animal Ethics Committees (AEC) were interviewed via 
telephone concerning how they prioritized reduction versus refinement in connection with 
toxicological experiments. The interviews were based on a fictitious one-week study in rats. The 
committee members were asked to evaluate the ethical impact of nine different clinical signs, 
each having one mild and one severe variant, and for each sign an ethical weight was 
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determined as how many animals free from clinical signs would entail the same ethical cost as a 
single animal experiencing the sign. The ethical weights assigned by the different member 
categories (researchers, political representatives and laypersons representing animal welfare 
organizations) were evaluated with Kruskal-Wallis tests. 
In Paper V various study designs were evaluated using Monte Carlo simulations of quantal 
data.  The designs did not have the same number of animals as is the case with most studies on 
experimental design, instead they had the same estimated ethical cost. The incidence of 
hepatocellular carcinoma and mononuclear cell leukemia in male rats (i.e. the same data as in 
Paper II), were used to define the true curve. The loglogistic model was included as a “true” 
dose-response model in the simulation step. All six models used in Paper II were fitted to the 
simulated data, and the BMD estimated from each model were averaged using an AIC based 
methodology. Several different study designs were evaluated, all having approximately the 
same ethical cost as a study with 200 animals evenly distributed to four dose groups at a 
medium-low dose placement. The ethical cost of a design was estimated in the basis of with 
ethical weights of 1, 4, 16, 64 or 256, based on the result from paper IV. The “true” curves were 
used to define the ethical cost of the studies, i.e. this cost of exposing to a certain dose depended 
on the response at that dose. Both datasets on hepatocellular carcinoma, without a background 
incidence, as well as on mononuclear cell leukemia, with a background incidence, were used to 
define the true dose-response curve as well as to define a dose-ethical cost-curve. 
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4 RESULTS AND DISCUSSION 
4.1 MODELS FOR CONTINUOUS ENDPOINTS   
In Paper I we found that coverage rates (i.e. how often the estimated BMDL is lower than the 
true BMD) depended on the dose placements and the assumed coefficient of variation (CV). 
These rates were in many cases considerably lower than the theoretical 95%, indeed in some 
scenarios as low as 20%, due to the exclusion of a ceiling parameter. With lower doses, the 
ceiling parameter was often excluded from the model selected, often resulting in coverage rates 
that were quite poor. On the other hand the BMDL values were on only slightly higher than the 
true BMD. With higher doses, the ceiling parameter was identified more often, so the coverage 
rates were closer to the expected 95%. However, when the ceiling parameter was excluded, the 
BMDLs were even less protective. Although the coverage of the BMDLs were somewhat 
disturbing, the situation with the NOAELs was generally worse. 
Less than nominal coverage rates are especially problematic from the point-of-view of the 
EFSA which generally supports a conservative approach to model selection, advocating the 
model with the lowest BMDL in cases where several model fits the data (EFSA, 2009). Thus 
the BMDLs selected using EFSAs guidelines would be expected to be conservative in general, 
but this is not the case as they don’t advocate the use of the model with lowest BMDL within a 
nested set, but instead advocating the selection one model from a nested set using likelihood-
ratio tests.  
Our findings on the BMDL coverage rates favor the use of a ceiling parameter (c) in dose–effect 
analysis, although this is not always entirely unproblematic. Within the nested set of exponential 
models, the ceiling parameter will be excluded if the data do not provide a significant amount of 
information about this parameter. Obviously, if the c-parameter is always included, the 
likelihood curve will sometimes be very flat due to the lack of information about the parameter 
which will lead to problems with model convergence.  
However, a lack of convergence should not automatically lead to dismissal of the result of the 
model fit, since it is the exact value of the c-parameter that is not of interest in BMD modeling, 
but rather the BMDL which is not much influenced by the exact value of an uninformative c-
parameter.  
More problematic is the fact that the overparametrization increases the risk of errors in the 
confidence interval estimated by the profile likelihood procedure, if the shape-determining d-
parameter is included as well.  The risk of obtaining such erroneous confidence intervals could 
potentially be avoided by starting the numerical estimations during the confidence interval 
estimations at different points in the parameter space, at least in those cases where there is a 
sharp drop in the profile likelihood curve.  
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Another issue with the 4-parameter models, that includes both a ceiling parameter (c) and a 
shape-determining parameter (d), is that the confidence intervals can be very broad, especially if 
the d-parameter is unrestricted.  From a precautionary perspective such a wide confidence 
interval and very low BMDL could be reasonable. The BMDL should reflect the lower limit of 
the risk and if the data do not support the absence of effects at low doses, then the BMDL value 
should be low. However, from a regulatory perspective it would be unfortunate if RfD based on 
continuous data differ from RfD obtained with quantal data (Crump, 2002), and since the 4-
parameter models are much more flexible RfD based on these could be considerably more 
conservative.  
Broad confidence intervals could be restricted by including prior information concerning the 
dose-effect relationship. This could either be done by including historical datasets on the same 
endpoint (Slob, 2014a; Slob and Setzer, 2014) or by including endpoint specific limits to the 
model parameters. However, both of these solutions require use of prior information and 
increases the demand of expert knowledge needed for the BMD analysis.  
It is also possible that always including d-parameter and allowing it to be lower than 1, instead 
of always including the c-parameter, may provide a model with enough flexibility to result in 
reasonable coverage rates.  
Yet, another approach would be to determine BMDs utilizing non-parametric approaches, but 
these can also result in unnecessarily wide confidence intervals (Slob and Setzer, 2014).  
4.2 BMD AND EXPERIMENTAL DESIGN  
Our major findings concerning study design in Paper II and Paper III, as well as relevant 
findings by others, are listed in Table 3. Paper II, with quantal data, indicates that it is 
important to include doses close to the targeted BMD, or a bit above the targeted BMD if there 
is a high background incidence. This is in line with the conclusions by Slob (2005)  and 
Kavlock and colleagues (1996). Shao and Small (2012) found that the best design for one of 
their two datasets had the lowest dose group much higher on the dose-response scale. However, 
Shao and Small used a different quality metric (the difference between the 95
th
 and 5
th
 percentile 
of the BMD estimates) and that can possibly contribute to the difference in the results.  
Moreover, Paper II and Paper III indicate that it is important to include higher doses with a 
clear response as well, which is in agreement with the findings of others (Dette et al., 2009; 
Holland-Letz and Kopp-Schneider, 2015; Krewski et al., 2002; Shao and Small, 2012; Slob et 
al., 2005).  
Our observation that dose groups of unequal size, with a larger number of animals close to or 
above the BMD, is generally in agreement with previous reports (Dette et al., 2009; Kavlock et 
al., 1996; Krewski et al., 2002; Weller et al., 1995).  However, Paper II indicates that this 
scientific gain is quite small with quantal data, as was also observed by Shao and Small (2012). 
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The other studies did not state how big the difference was between an equal distribution of 
animals and an optimal uneven distribution. Paper III showed that with continuous data this 
gain was greater and moreover, it seems as the control groups is more important for continuous 
data than for quantal data.    
Using distress as a criterion for evaluating designs has not been done before. In many of the 
scenarios in Papers II and III, the best design with more animals receiving a dose close to the 
BMD, showed less estimated distress. It was shown that although the improvement was quite 
limited there is a potential to use BMD-aligned experimental design as a means to refine 
toxicity testing. However, this was most clearly evident when the doses were high in general, in 
the range where a clear effect could be observed and where distress also can be expected to be 
higher.  
Some of the previous studies have included parameter or model uncertainties in the modeling. 
Shao and Small (2012) combined two models as “true” models, but did not take into account 
potential uncertainties in the location of the dose-response curve. Kuljus and colleagues (2006) 
as well as Holland-Letz and Kopp-Schneider (2015) included uncertainty in the steepness 
paramater, but their suggested optimal designs did not take into account the uncertainty in the 
dose placement. Dette and colleagues (2009) took uncertainties into account when determining 
optimal designs in a part of their study.  However the uncertainties were very small, they are 
much larger when designing real toxicity experiments. In Paper II and Paper III we to some 
extent took dose placement uncertainty into account by investigating the same designs at 
different dose placements, although we did not consider a continuous range as Dette and 
colleagues did. Further investigation of the designs of studies should ideally take into account 
realistic uncertainties in the parameter estimates, and ideally also model uncertainties.  
Various approaches on how to incorporate prior information or how to combine different 
datasets have been described (Slob and Setzer, 2014; Wheeler and Bailer, 2009a). The influence 
on such approaches on experimental design aligned to BMD has however not been examined 
and warrants investigation. Wang and colleagues (2013) proposed optimization of the design of 
a sequential experiment by performing by designing sequential design, i.e. the second stage is 
designed after the first, but this approach does not take variability between the experimental 
stages into account.  
This issue of differences between experimental stages performed in the same laboratory is 
analogous to designing new studies on the basis of previous ones. The uncertainties are larger in 
the latter case, but not fundamentally different. Since these uncertainties need to be included in 
the development of experimental designs their quantification in desirable.  
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Table 3. Summary of previous and present studies concerning the estimation of BMD. “-“ = Not investigated. 
Article Methods Results 
Type of 
data 
Evaluated 
simulated 
data or 
minimized 
expected 
variance? 
Was model 
uncertainty 
included the 
estimations
? 
Were 
BMDLs 
calculated
? 
Was 
animal 
distress 
considered
? 
Did more dose 
groups give better 
estimates? 
Are the 
estimates 
better with a 
dose closer to 
the BMD? 
Are high doses 
important? 
Does unequal 
distribution of 
animals have an 
impact on 
quality? 
(Weller et 
al., 1995) 
Quantal Both. No Yes No More groups resulted 
in better accuracy, 
but worse precision. 
- - Yes, few animals 
needed at the 
high dose. 
(Kavlock 
et al., 
1996) 
Quantal Evaluated 
simulated data 
No Yes No Not necessarily, it 
depended on the 
situation.  
Yes Doses close to 
the BMD are 
more important.  
 - 
(Krewski 
et al., 
2002) 
Quantal Minimized 
expected 
variance  
No No No 3-4 groups are more 
efficient than 5-7 
groups. 
Sometimes, but 
not always.  
Yes Yes, fewer 
animals needed 
at the high dose. 
(Dette et 
al., 2009) 
Quantal Minimized 
expected 
variance 
No No No Sometimes 4 doses 
are better than 3.  
- Yes Yes, few animals 
are needed at the 
highest dose.  
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(Shao and 
Small, 
2012) 
Quantal Evaluated 
simulated data 
Yes, used 
two models 
weighed 
with a BMA 
approach.  
No No Yes. On one 
occasion the 
best design 
involved a dose 
almost as high 
as ED50.  
Yes Only minor 
effect. 
(Slob, 
2014b) 
Quantal Evaluated 
simulated data 
No Yes No Not clearly.  - - - 
(Slob et 
al., 2005)  
Continuous Evaluated 
simulated data 
Yes, model 
selection 
based nested 
set of 
models 
Yes No More dose groups 
reduced the risk of 
poor dose placement. 
 
Most often, yes. Yes - 
(Kuljus et 
al., 2006) 
Continuous Minimized 
expected 
variance 
No No No > 4 dose groups 
better when 
parameter values 
were uncertain. 
No, at least not 
a strong trend.  
- - 
(Holland-
Letz and 
Kopp-
Schneider, 
2015) 
Continuous Minimized 
expected 
variance 
Yes No No Yes, > 4 dose groups 
were preferred when 
parameter values 
were uncertain. 
No Yes Yes, but there 
was no clear 
trends regarding 
how to distribute 
the animals. 
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Included in this thesis 
Kalantari 
et al  
(Paper II) 
Quantal Evaluated 
simulated 
data 
Yes, 6 models 
weighted 
together with 
an AIC-based 
model 
averaging 
approach. 
Yes Yes - Yes Yes Small effect on 
BMD, but 
potential ethical 
benefit 
Ringblom 
et al.  
(Paper 
III) 
 
Continuous Evaluated 
simulated 
data 
Yes, 4 models 
together with 
AIC-based 
model 
averaging 
approach. 
No Yes - Not 
necessarily, 
but it was 
advantageous 
with many 
animals closer 
to the BMD.  
Yes More 
pronounced 
effect on BMD 
than in Paper II. 
Ringblom 
et al.  
(Paper V) 
Quantal Evaluated 
simulated 
data 
Yes, 6 models 
together with 
an AIC-based 
model 
averaging 
approach. 
Yes Yes - Yes Yes, if there was 
a background 
incidence of 
distress. Less so 
without  a  
background 
incidence of 
distress. 
Yes, large effect 
since few high 
dose animals 
was converted to 
more low dose 
animals. 
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4.3 REDUCTION VERSUS REFINEMENT 
In 47 interviews with members of the Swedish AECs in Paper IV, priorization between 
reduction and refinement varied widely. One researcher and one political representative 
always prioritized reduction and 3 researchers, 1 political representative and 2 representatives 
of animal welfare organizations always prioritized refinement. The responses of the 
remaining 39 participants implied that a limited increase in animal numbers in some cases 
could be acceptable if the individual animal distress was reduced.  
The median ethical weights, that is how many animals not showing a clinical sign that 
entailed the same ethical cost as 1 animal with the clinical sign, was 2-4 for the milder 
version of the signs and 5-20 for the more severe version of the signs. There were no 
statistically significant difference between the magnitudes of the ethical weights assigned by 
different member categories of members (researchers, political representatives and 
representatives of animal welfare organizations) the within group variation was large 
compared to the between group variation. There where however a small trend that the 
political representatives assigned lower ethical weights than the other committee members.  
These similarities between the groups raise the question as to whether there is any reason to 
include laypersons in the AECs. Personally, I believe, in agreement with others (Hansen, 
2013), that the laypersons play an important role and that the committees should not consist 
of researchers alone. When evaluating research protocols, the members must weight the harm 
of an animal experiment against the scientific benefits. Our participants only weighted harm 
against harm, which is not the same thing.  
8 participants (5 researchers, 1 politically nominated layperson and 2 laypersons nominated 
by animal welfare organizations), found the questions to be too hard to answer and did not 
complete the interview, as also happens in connection with PTO studies on human health 
(Damschroder et al., 2007).  Such studies involve making decisions concerning the health of 
other humans and it is not surprising that many find PTOs difficult and unpleasant (Nord, 
1995), nor is it surprising that this is the case for questions regarding animal experimentation 
as well, which is potentially even more sensitive than questions regarding health care.  
In an examination, on the balance between reduction and refinement, Franco and Olsson 
(2014) asked participants in a Laboratory Animal Science course if they ethically preferred 
performing a stressful experiment with no permanent effects 20 times on one animal or once 
in 20 animals. If the animals were mice, a slight majority preferred refinement, using more 
animals, whereas if the animals were primates or dogs more favored reduction. Franco and 
Olsson note that this difference might reflect considerations other than purely ethical ones, 
such as financial and logistical considerations, but some ethical differences might still be 
truly ethical. This indicates that the size of ethical weights could be species specific. Also, 
completely different clinical signs may be needed for different species.  
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It is also quite possible that cultural differences between countries regarding reduction versus 
refinement exist. For instance, there are considerable differences among the residents in the 
different countries of Europe concerning the opinions on human euthanasia (Cohen et al., 
2006). This question has, of course, other dimensions than animal euthanasia and reduction 
versus refinement in animal experiments, but the value of a life and wrongness of killing is 
involved in both cases. According to the report by Cohen, Swedes are more positive to 
euthanasia than the inhabitants in most other European countries, and one wonders whether 
this might also be the case with respect to refinement of animal experimentation. If so, the 
ethical weights determined in our study would be expected to be higher than if the study was 
performed in a similar test population in a different country, for instance in southern Europe. 
Previously statements on reduction and refinement have mostly been of qualitative nature. 
However in some situations qualitative statements are not informative enough, for instance 
when it comes to evaluating several experimental setups or test strategies. The determined 
ethical weights are up for criticism, for instance regarding their accuracy. However being up 
to criticism in some sense positive, compared to mere qualitative statements that often lack 
specificity and evaluability. 
In Paper V, we used the quantitative ethical weights determined in Paper IV to investigate 
how toxicity tests can be designed taking into account both the number of animals used and 
the experiences of the individual animals. We evaluated ethical weights of 1,4,16,64 and 256. 
The results show that the optimal dose placement was heavily dependent on the ethical 
weight of the sign determining the ethical cost and the background incidence of that clinical 
sign. When the distress of the individual animal was not considered at all (ethical weight=1) 
it was preferable to place the doses relatively high on the dose-response scale with the mid 
dose group around or even above the ED50. Already the use of an ethical weight of 4, made it 
generally preferable to have the mid dose placed below the true BMD (ED10), if there was no 
background incidence of distress and no background incidence of the toxicological endpoint. 
However, if it was assumed that there was distress present already in the control group, there 
is not a lot to gain by moving animals to lower doses.  
The use of even higher ethical made it more advantageous to use more animals at lower 
doses, but it was only in one case where it was preferable to use the lowest dose placement 
tested, with the high dose group around the true BMD. In that case there were more than 
1000 animals in the study and it seems unlikely that such study would be performed in 
practice.  
The ethical weights determined in Paper IV were based on one-week experiments on eight 
week old rats, while the dose-response data in Paper V was from a two-year study. It is not 
obvious that these weights are directly transferable in this manner. In a two-year study the 
animals could suffer distress for a longer period of time, but they also live longer, i.e. might 
have longer periods of life worth living as well, balancing the enhanced stress out from a 
utilitarian perspective. 
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The degree to which the ethical weights would need to be adjusted to be appropriate for a 2-
year study, remains an open question. On the other hand we tested a wide range of ethical 
weights (1,4,16,64,256) in Paper V, so even if the weights are changed, it is still possible to 
draw conclusions about study designs.  
Are the results presented in Paper V relevant also for shorter studies, even though the dose-
response data are from a longer study? In principle, they should be. The background 
responses can surely be the same for endpoints relevant to shorter exposures. At the same 
time the slope of the dose-response curves could differ for different endpoints and different 
experimental setups. Nothing has yet been published concerning the shape of the quantal 
dose-response data, although Slob and Setzer mention that they are working on this (Slob and 
Setzer, 2014). In the absence of such data, I find no compelling reason to believe that the 
shape of the dose-response curve for carcinogenicity should differ markedly at higher doses 
compared to other quantal responses.  
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4.4 METHODOLOGICAL CONSIDERATIONS 
4.4.1 Assumptions regarding dose-response models 
In Papers I-III and V we studied BMD modeling using Monte Carlo simulations meant to 
emulate real life experiments. Investigating the performance of different designs by 
performing the experiments with real animals may look favorable for obvious reasons. 
However, computer simulations offer the advantage “true” dose-response relationship is 
known by definition, providing a reference for the results. Also, with computer simulations it 
is possible to investigate many possible situations (i.e., shapes of dose-response curves, 
combinations of designs, etc.) compared to what can be realistically evaluated with real 
toxicity data. The results obtained with a simulation approach are of course dependent on the 
assumptions made in the simulations, e.g. the true models used, the values of the parameters 
and variation in these models etc. In these papers of this thesis we employed several different 
assumptions depending on the specific aims of each project. 
In Papers II and V the true models originate from two actual datasets with different 
background incidences in an NTP cancer study on F344 rats exposed to Furan (NTP, 1993). 
In Paper II six different models of varying steepness were fitted to each dataset, giving rise 
to 12 different dose-response curves, with different steepness. The F344 strain is an inbred 
strain and it is therefore likely that the dose-response curve is steeper than it would be from 
an outbred strain or human population. In Paper V we fitted only the loglogistic model to the 
two different endpoints, giving rise to two different true curves, one without and the other 
with a background incidence.  
In Paper I we employed a dose-effects model already used in a similar simulation study 
(Slob et al., 2005), the choice of  parameters and CV in previously published article was 
based on a database of dose-effect data. We used CVs of 5%, 10% and 15%. It has been 
suggested that the size of the CV covaries with the difference between the maximum effect 
and the background effect (Slob, 2014b) . If so, it is likely that 5% scenario is the most 
realistic one.  
In Paper III, we used four hypothetical curves (exponential, Hill, power and polynomial). 
The exponential and Hill models are realistic according to Slob & Setzer (2014). We also 
used the power and polynomial models in both the simulation and estimation step. It could 
have been argued that both of these models should have been omitted on the basis of the 
findings by Slob and Setzer (2014), who showed that a vast array of dose-effect relationships 
can be adequately described using the four-parameter exponential and Hill models. The 
power and polynomial models were included anyway since it is common practice to use these 
in dose-effect modeling.  
While the results in Papers I and III are dependent on the model parameters, it can be 
demonstrated that the results from the simulations based on continuous data are valid also for 
situations with different CVs, as long as the CES and ceiling parameter (c) is changed 
appropriately as well (see Slob, 2005 for details). 
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In contrast to the case for quantal data, the choice of CV and the assumptions regarding the 
distribution of the data both matter for continuous data. We assumed that the data are 
distributed lognormally. Shao and colleagues (2013) demonstrated that the assumption 
regarding normality or lognormality has limited impact when the CV is small (CV=10%), 
which was the case in Paper I and Paper III. 
4.4.2 What constitutes a good design? 
Different investigations in the literature have used difference methods and different quality 
metrics to evaluate different experimental designs. In Paper II, III and V we explored 
experimental designs using Monte Carlo simulations and we employed the RMSE as the 
primary quality metric. Minimizing a design criterion, such as the expected variance of the 
parameter estimates, was an alternative to the simulations, but simulations were chosen as 
they reflect actual experiments more closely. Minimizing the expected variance gives no 
information regarding the frequency of statistically significant dose-response relationships or 
the BMDLs.  
We employed RMSE of the BMD as the primary quality metric in our simulations. The 
advantage of using the RMSE is that it measures both accuracy and precision of the BMD 
estimate. The RMSE (or MSE) has also been used as a quality metric in earlier simulation 
studies involving BMD estimations (Fung et al., 1998; Guha et al., 2013; Kavlock et al., 
1996).  It might appear to be more realistic to primarily employ a metric based on the BMDL 
rather than the BMD since the lower confidence interval is the value used in risk assessment 
and BMDU/BMDL or BMD/BMDL ratios are commonly used to assess the precision in 
BMD analysis. However, these metrics only assess the apparent precision and not real 
precision and they should therefore be used with caution as quality metrics in simulations. 
For instance the BMDU/BMDL ratio can be very low, indicating good estimation, while the 
“true” BMD is actually outside of the BMDL-BMDU interval (as shown in Paper I). 
An alternative approach has been proposed by Slob(2014a). He proposes that minimizing the 
“true”BMD/BMDL ratio provide good evaluations in BMD simulations. Following this 
suggestion literally is, however, not recommended since it implies that higher BMDLs are 
always better and that anti-conservative approaches are always preferred. It would perhaps be 
sounder to use the coverage rates or the “true”BMD/BMDL95th percentile as quality metrics. 
Although a coverage of 95% and a “true”BMD/BMDL95th percentile=1 seems favored it is 
unclear whether a coverage of 90% and a “true”BMD/BMDL95th percentile=0.9 is better or 
worse than a coverage of 99% “true”BMD/BMDL95th percentile=1.3. In addition, results based 
on coverage rates will be heavily dependent on the model selection or averaging procedure.  
The procedure we applied to weight BMDLs together is not formally correct as the BMDL is 
“not an independent random variable but a statistic of the variable BMD”(Shao and Gift, 
2014), although it has been suggested and used by others as well (Bailer et al., 2005a; Bailer 
et al., 2005b; Wheeler and Bailer, 2009b). RMSEs based on BMD estimates are also 
influenced by the choice of selection or averaging procedure, but less so.  
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In Paper III some of the BMD estimates were very high due to the fact that the dose-effect 
curve was very flat. Consequently we set a limit on the BMDs for certain outlier datasets, 
treating them as exhibiting lower BMDs than they actually did. Otherwise, the quality of the 
designs would have depended solely on single outlier values. A different solution would be to 
keep all of the BMDs and calculate the Root Median Squared Errors instead of the more 
commonly used Root Mean Squared Errors, as medians are less sensitive to outliers.   
In Paper II and V we left out models with poor fits in the model averaging, as suggested by 
Wheeler and Bailer (2009b).  Accordingly for certain datasets no models gave an acceptable 
model fit and thus there were no BMDs or BMDLs for these datasets. In Paper II these 
simulations without a BMDAIC were excluded from the RMSE calculations. In Paper V we 
used an alternative approach where they were treated as having a BMDAIC to 10 interquartile 
ranges higher than the average BMDAIC for that particular design, in order to penalize 
simulations without a dose-response trend as false negatives are negative outcomes. 
BMDU/BMDL ratios, a measure of apparent precision, were used as secondary quality 
metrics in Papers II and V, but not in Paper III where preliminary simulations indicated that 
confidence interval calculations sometimes resulted in erroneous BMDLs and BMDUs due to 
numerical problems when calculating the profile likelihood curve. With real data such 
erroneous confidence intervals can be identified by visual inspection of the profile likelihood 
curve, but in the present case it was not possible to visually inspect the output of all BMD 
calculations. In retrospect, we could have accepted the erroneous BMDL, since as long as 
they are relatively few in number, they distort the median BMDU/BMDL ratios only slightly.   
4.4.3 Trade-off interviews 
In Paper IV we determined cardinal weights for the ethical cost of animal experiments by 
trade off interviews with the members of the Swedish AECs. We chose the interview group 
based on that they are used to evaluate situations regarding animal ethics and they also 
include members of different backgrounds and beliefs. The participants in our study match 
the composition in the Swedish AECs fairly well when it comes to the fraction of members 
being researchers, politicians or animal welfare representatives and there were participants 
from all regional committees. It is still possible that those who agreed to participate are not 
representative. Furthermore, the representativeness of committee members may not be ideal. 
For instance, maybe a more ideal test population would include individuals with other 
backgrounds as well, such as ethicists and ethologists. 
We conducted interviews, instead of written surveys, as trade-off questions are easy to 
misunderstand. For instance, in a PTO investigation involving written surveys by Ubel and 
colleagues (2002), two thirds of the responses of showed inconsistencies and had to be 
excluded. Consequently, interviews are the gold standard for trade-off investigations allowing 
the task to be explained more thoroughly and inconsistences to be addressed.  
However, interviews can be quite time-consuming and moreover, involve a risk that the 
interviewer influences the participants (Damschroder et al., 2004). The answers obtained at 
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later stages of a PTO study can be influenced by anchoring these numerically to earlier 
answers (Ubel et al., 2001; Ubel et al., 2002). In other words once a participant has given a 
numerical value, the next choice will be anchored to that value.  Alternatively, participants 
can anchor their values to numerical values provided, e.g. when a bidding game (ping-pong) 
methodology, a common search elicitation in trade-off studies is utilized. In such a bidding 
game the participants answers iterative yes/no questions, e.g. as follows:  
1. Would 11 animals experiencing mild tremor entail a higher ethical cost than 10 
animals experiencing severe tremor?  
2. Would 1 000 000 animals experiencing mild tremor entail a higher ethical cost 
than 10 animals experiencing severe tremor? 
3. Would 20 animals experiencing mild tremor entail a higher ethical cost than 10 
animals experiencing severe tremor? 
4. Would 10 000 animals experiencing mild tremor entail a higher ethical cost 
than 10 animals experiencing severe tremor? 
and so on until a point of indifference in reached. Since our questions were not framed 
following the ping-pong approach, the participants could not have anchored their answer to a 
number provided by the interviewer. The ping-pong methodology is also more time 
consuming method. On the other hand the participants had to decide their point-of-
indifference directly, which can be more difficult.  
Possibly, our participants could have anchored their later answers to their earlier ones and we 
might have gotten different weights if the questions had been asked in a different order. 
Participant fatigue could have a similar effect. A solution to both of these problems would 
have been to ask the questions in random order, but that would have been stressing to the 
interviewer thereby increasing the risk for other mistakes and in addition it would have 
increased the documentation of the responses. 
Others have shown that PTO responses often deviates from cardinal transitivity, i.e. that one 
such response cannot be accurately inferred from two other (Baron et al., 2001; Dolan and 
Tsuchiya, 2003; Schwarzinger et al., 2004; Ubel et al., 1996). We therefore included built-in 
checks for cardinal transitivity between the mild and severe clinical signs. There was, 
however, no direct check for cardinal transitivity between different types of signs, although 
many participants to some degree provided such checks explicitly by thinking out loud during 
the interview. Furthermore, it remains to be evaluated whether our questions exhibits a good 
test re-test reliability and whether the results are reproducible.  
There might be a strong random element in the trade-off studies, but since random elements 
do not introduce bias, median equivalence numbers in large groups of people may be more 
reliable (Nord, 1995). Although our group was not so large, we interviewed at least a 
reasonable part (~24%) of the members of the Swedish AECs. 
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While the clinical signs were defined and described in the same manner to all participants 
they may nonetheless have been interpreted differently, which might have influenced the 
weights. This issue can potentially be solved by showing videos of animals experiencing the 
clinical signs, but many signs are difficult for an unskilled professional to interpret, so most 
laypersons in the AECs would likely have struggled interpreting such videos. 
4.4.4 Other issues related to ethical cost of animal distress 
An unavoidable weakness of our approach is that the ethical weights are assigned by humans, 
since we could not ask the animals about their opinion. Accordingly, the weights are not only 
subjective, but also assigned by subjects that are not ideal and whose appraisals could, for 
instance, be distorted by anthropomorphic tendencies. Such anthropomorphism could, for 
example lead to an ethical weight for “weight loss” that is too low since many humans would 
not mind losing a few kilos of weight themselves. 
There are more objective physiological measures utilized to assess the stress experienced by 
animals during experiments, such as the grimace scales (Keating et al., 2012; Langford et al., 
2010; Sotocinal et al., 2011) and non-invasive measurement of metabolites of stress hormone 
in feces and amylase levels in saliva (Kolbe et al., 2015; Matsuura et al., 2012). Alterations in 
stress hormone levels can however  be caused by both pleasant and unpleasant situations 
(Dawkins, 2008). Moreover, no measure such as these could directly be used as ethical 
weights, since we cannot say anything about if having two animals with a certain facial 
expression or hormone level are equally regrettable as having one animal with a worse facial 
expression or higher hormonal level. 
It is also possible to conduct preference tests concerning how much effort an animal is 
willing to put in to achieve something positive or avoid something negative. Such a study 
could be performed to evaluate the relative severity of some of the clinical signs. Such tests 
would, however, be ethically questionable, at best. 
We based our ethical weights on clinical signs since these are recorded in toxicity tests for 
everyday assessment of animal welfare and determination of the suffering of the animal 
surpasses what deemed acceptable in the study, so that the animal should be humanely killed 
(OECD, 2002). Of course, other factors not picked up directly by our ethical weights, such as 
the size of the cages, presence of environmental enrichment and cage-mates also contribute to 
animal welfare (Balcombe, 2006).  In addition, lack of clinical signs does not necessarily 
mean absence of distress. For example, animals can suppress the expressions of distress to 
deceive predators.  
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5 CONCLUSION 
The current use of nested models in the determination of BMDs for continuous endpoints 
could lead to coverage rates below nominal level due to the fact that the simpler models with 
fewer parameters are not flexible enough. Since coverage rates below the nominal level leads 
to underestimation of the risk, models of lower order should be used with caution in risk 
assessment. In addition, it is clearly shown that the NOAEL approach is even more 
problematic.  
To establish BMD values with high quality, it is important to include a dose located relatively 
high on the dose-response scale.  Employing dose groups of unequal size can also slightly 
increase the quality of BMD estimates or conversely allow the same quality with fewer 
animals. In general, it is preferable to place more animals in the dose groups around the true 
BMD, or a bit above the BMD if there is a high background incidence of the selected 
endpoint. Such designs could also be utilized to reduce the animal distress.  
Prioritization between reduction and refinement, expressed as ethical weights for clinical 
signs, varies considerably among the member of the Swedish AECs. The median ethical 
weights were 2-4 for the mild versions of the clinical signs and 5-20 for the severe versions. 
Some participants assigned an ethical weight of 1 to all signs (always giving priority to 
reduction) while others assigned infinity to all signs (always giving priority to refinement). 
No statistically significant difference was observed between the three categories of 
committee members (researchers, political representatives and representatives of animal 
welfare organizations) regarding the magnitude of the ethical weights. 
Ethical weights with cardinal properties can be used to explore designs for toxicity tests that 
optimize the ethical cost in terms of both number of animals and their distress. These 
optimized designs are heavily dependent on what constitutes the ethical cost, and the relative 
ethical importance of those costs. Using more animals, but at lower doses, can be ethically 
justifiable. Even though it can be ethically justifiable to use a very large number of animals at 
very low doses (all doses below the BMD), the large number of animals required render such 
an approach impractical in reality.  
 
  
  33 
6 FUTURE RESEARCH PERSPECTIVES 
Based on the results in this thesis several areas for further investigation and research have 
been identified. In general, the BMD approach and the underlying strategies for model 
selection need to be improved and harmonized. In addition, the alignment between BMD 
analysis and experimental design needs to be further studied and implemented in guidance 
documents. Moreover, the 3R-principles could be used as a factor when evaluating 
experimental design and approaches for dose-response modelling. The following paragraphs 
include specific suggestions and ideas for research studies within this field of research. 
The best way to select a BMDL, to use as a PoD, from continuous data needs to be elucidated 
further.  This could be done by performing large studies that compare the effects of different 
approaches, similar to the ones performed in connection to their modeling averaging 
workshop (US EPA, 2015), including (e.g. non-parametric approaches, model averaging of 
the currently used models etc) on the coverage rates of the BMDLs.   
Further investigations concerning how to design experiments on the basis of prior data, such 
as previous studies on similar compounds and the same endpoint are warranted.  Such 
investigations should ideally take into account parameter uncertainty, especially with regard 
to the potency parameter/dose placement. In this context, additional analysis of historical data 
as performed by Slob and Setzer (2014) would be valuable as would studies designed to 
quantify the uncertainties that can be expected when designing studies.  
Our study on ethical weights in Paper IV is the first of its kind and there are numerous ways 
to expand upon it. First this investigation could be repeated in different settings, with 
participants of different types and/or from different countries. Paper IV also only considered 
a one week study in rats. The impact of other study durations and experiments concerning 
different species also needs to be further elucidated. Also, we focused on the clinical signs 
experienced by the animals during the experiments and additional factors can influence the 
prioritization between reduction and refinement.  
In Paper II-III and V, we investigated designs using Monte Carlo simulations. An 
alternative approach would be to perform a classical optimal design study using a design 
criterion based on the expected variance of the parameters. Such an investigation, with ethical 
costs as in Paper V, could help limit the otherwise impractically large number of 
combinations of designs, ethical weights, dose placements and curves that needs to be tested.  
In Paper V we investigated the impact of ethical weights on the performance of different 
with quantal data and a similar study with continuous data is warranted.  
Paper V was a study on the ethical cost-efficiency of a single dose-response study. Nordberg 
and colleagues (2008) have investigated the monetary cost-efficiency of different tests in 
relation to the criteria for labelling and classification. Animal welfare could be included in 
such strategies as well. To do so the ethical cost of different tests (acute, subacute, irritation 
etc) needs to be estimated. Gabbert and van Ierland (2010) made a similar investigation on 
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mutagenicity tests comparing the efficiency of in vitro and in vivo tests. However, their 
investigation only included number of animals as a proxy for animal welfare. The ethical cost 
of the different type of in vivo studies, depending on the expected distress of the animals,  
could be included as a factor as well.  
Monetary cost could also be included in the analysis such as the ones in Paper V, by setting 
monetary cost boundaries, for example by setting a limit on the numbers used as well as a 
limit on the ethical cost of the study. 
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